Immunic highlights positive Phase 2 trial results for vidofludimus calcium at UEGW 2023

Immunic Inc (NASDAQ:IMUX) shared encouraging results from their phase 2 CALDOSE-1 trial of vidofludimus calcium (IMU-838) during an oral presentation at the United European Gastroenterology Week 2023. The trial showcased statistically significant efficacy of vidofludimus calcium compared to a placebo, reinforcing its promising safety and tolerability profile for potential use in ulcerative colitis (UC) and other inflammatory bowel disease applications.